Novartis (NVS) Stock Research

Wednesday

Amgen price target raised by $18 at Morgan Stanley, here's why

Aug 5, 7:36 AM

Over a week ago

Novartis says FDA approves Pluvicto for PSMA+ metastatic prostate cancer

Jul 31, 4:33 PM

Novartis price target raised by CHF 10 at Citi

Jul 22, 2:44 PM

Trump Trade: U.S. to impose 100% tariff on imported generic drugs

+27

Jul 22, 10:06 AM

Trump to set 100% tariff on generic drugs brought into U.S. starting in 2028

+10

Jul 21, 7:01 PM

What You Missed On Wall Street On Tuesday

+24

Jul 21, 4:24 PM

Midday Fly By: GM, 3M, Hasbro all post beat and raise reports

+23

Jul 21, 11:58 AM

Morning Movers: Equifax sinks following second quarter earnings

+11

Jul 21, 9:02 AM

Novartis reaffirms FY26 guidance

Jul 21, 5:51 AM

Novartis reports Q2 core EPS $2.41 vs. $2.42 last year

Jul 21, 5:50 AM

Maxim upgrades Akari Therapeutics to Buy on AKTX-101 data, ADC M&A

Jul 20, 8:54 AM

Novartis agrees to acquire Myricx Bio for up to $1.5B

Jul 6, 5:25 AM

Novartis to acquire Myricx Bio for $1.1B upfront

Jul 6, 5:22 AM

Novartis receives EC approval for Itvisma for spinal muscular atrophy

Jul 2, 6:27 AM

Anthropic takes aim at pharma industry with Claude Science, STAT reports

Jun 30, 1:13 PM

BTIG says others may be interested in Apogee Therapeutics

Jun 22, 6:34 AM

CMS proposes to lock in lower prices in Medicare drug price negotiation program

Jun 15, 12:08 PM

Novartis announces Rhapsido met primary endpoints in RemIND trial

Jun 12, 6:56 AM

Novartis announces biomarker cohort in study of del-brax met primary endpoint

Jun 11, 6:41 AM

Novartis, Orionis enter collaboration for molecular glue medicines

Jun 10, 7:05 AM

Acting FDA head vows to block political interference, Endpoint News says

+23

Jun 4, 2:11 PM

Novartis reports final 2.5-year Phase III ALIGN results on Vanrafia

Jun 4, 6:25 AM

FDA issues draft guidance to help accelerated cell, gene therapies for patients

+24

Jun 2, 9:40 AM

Novartis announces 144-week data from ASC4FIRST trial of Scemblix

Jun 1, 7:29 AM

Novartis announces results on rPFS improvements across subgroups with Pluvicto

May 31, 5:46 PM

Robust R&D Pipeline: High investment in research and development continually replenishes its pipeline with new, innovative medicines addressing significant unmet medical needs.

Leading Therapeutic Areas: Holds strong market positions in key therapeutic areas such as oncology, cardiovascular, and immunology, ensuring significant market share and revenue stability.

Extensive Global Reach: Possesses a vast global commercial infrastructure, enabling broad market access and efficient distribution of its products across diverse international markets.

Research and Development Failure Risk: Novartis invests heavily in R&D, and the failure of clinical trials or inability to bring new products to market could significantly impact future revenue and growth.

Regulatory Approval and Compliance Risk: The company operates in a highly regulated environment, and failure to obtain or maintain necessary approvals, or non-compliance with health and safety regulations, could lead to fines, product recalls, or market withdrawal.

Patent Expiry and Generic Competition Risk: Key products face patent expiration, opening the door for generic competition which can drastically reduce sales and profitability for those brands.

Charts